Lofexidine

Lofexidine
Clinical data
Trade names	Britlofex, Lucemyra, others
AHFS/Drugs.com	Monograph
Routes of; administration	By mouth
ATC code	N07BC04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	>90%
Protein binding	80–90%
Metabolism	Liver (glucuronidation)
Elimination half-life	11 hours
Excretion	Kidney
Identifiers
	IUPAC name (RS)-2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole;
CAS Number	31036-80-3 ;
PubChem CID	30668;
DrugBank	DB04948 ;
ChemSpider	28460 ;
UNII	UI82K0T627;
KEGG	D08141 ;
ChEBI	CHEBI:51368 ;
ChEMBL	ChEMBL17860 ;
CompTox Dashboard (EPA)	DTXSID7023221 ;
Chemical and physical data
Formula	C11H12Cl2N2O
Molar mass	259.13 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES Clc2c(OC(C/1=N/CCN\1)C)c(Cl)ccc2;
	InChI InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15) ; Key:KSMAGQUYOIHWFS-UHFFFAOYSA-N ;
	(what is this?) (verify)

Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure; today, it is more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an α_2A-adrenergic receptor agonist. It was approved for use by the Food and Drug Administration in the United States in 2018, considering it to be a first-in-class medication.